Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tong Ren Tang Chinese Medicine CoFRA:TQR -1.39%72 5-Year Yield-on-Cost % is 9.12 as of Aug. 06, 2026, which is 172% above its 10-year median of 3.35. GuruFocus rates FRA:TQR with a GF Score™ of 72/100 and a GF Value™ of €1.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 513 Drug Manufacturers companies, Beijing Tong Ren Tang Chinese Medicine Co ranks better than 85.77% on this metric.
FRA:TQR's 5-Year Yield-on-Cost % is ranked better than 85.77% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs FRA:TQR: 9.12
Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Beijing Tong Ren Tang Chinese Medicine Co 5-Year Yield-on-Cost % Related Terms
FRA:TQR vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tong Ren Tang Chinese Medicine Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Tong Ren Tang Chinese Medicine Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Beijing Tong Ren Tang Chinese Medicine Co's 5-Year Yield-on-Cost % falls into.
Beijing Tong Ren Tang Chinese Medicine Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) has a 5-Year Yield-on-Cost % of 9.12 as of Aug. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beijing Tong Ren Tang Chinese Medicine Co and its competitors. This is 172% above median its historical median of 3.35. Over the past decade, Beijing Tong Ren Tang Chinese Medicine Co's 5-Year Yield-on-Cost % has ranged from 1.33 to 9.12. According to the industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #73 out of 513 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Beijing Tong Ren Tang Chinese Medicine Co's 5-Year Yield-on-Cost % too high?
Beijing Tong Ren Tang Chinese Medicine Co's current 5-Year Yield-on-Cost % of 9.12 is 172% above median its 10-year median of 3.35. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 9.12. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.35. Beijing Tong Ren Tang Chinese Medicine Co's value of 9.12 is 288.1% above this industry median. Based on the distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #73 out of 513 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tong Ren Tang Chinese Medicine Co has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tong Ren Tang Chinese Medicine Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #73 out of 513 companies for 5-Year Yield-on-Cost %. This places Beijing Tong Ren Tang Chinese Medicine Co in the top 14% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.35. Beijing Tong Ren Tang Chinese Medicine Co's value of 9.12 is 288.1% above this benchmark. Historically, Beijing Tong Ren Tang Chinese Medicine Co's own 5-Year Yield-on-Cost % has ranged from 1.33 to 9.12 over the past decade. While the company's 10-year median is 3.35 vs. the industry median of 2.35, Beijing Tong Ren Tang Chinese Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.35, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tong Ren Tang Chinese Medicine Co's current 5-Year Yield-on-Cost % of 9.12 is 288.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Beijing Tong Ren Tang Chinese Medicine Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tong Ren Tang Chinese Medicine Co's current 5-Year Yield-on-Cost % is 9.12, which is 172% above median its own 10-year median of 3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tong Ren Tang Chinese Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) is currently considered Significantly Undervalued. The stock's GF Value™ is €1.06, compared to a current price of €0.71 — trading 33% below its estimated fair value. The current 5-Year Yield-on-Cost % is 9.12, which is 172% above median its 10-year median of 3.35 and 288.1% above the Drug Manufacturers industry median of 2.35. Beijing Tong Ren Tang Chinese Medicine Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR), the current 5-Year Yield-on-Cost % is 9.12 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tong Ren Tang Chinese Medicine Co (FRA:TQR) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co stock appears to be undervalued.
The current stock price of €0.71 is trading 33% below its estimated GF Value™ of €1.06.
GuruFocus considers Beijing Tong Ren Tang Chinese Medicine Co to be Significantly Undervalued.
Key valuation signals for FRA:TQR:
5-Year Yield-on-Cost %: 9.12 (172% above median its 10-year median of 3.35)
GF Value™: €1.06 vs. price of €0.71 (33% below fair value)
Industry Position: 288.1% above the Drug Manufacturers median (#73 of 513)
No single metric tells the full story. See the FRA:TQR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products; Chinese Mainland (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Chinese Mainland and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd; and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.
72GF Score
Get the complete analysis for FRA:TQR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TQR has been successfully added to your 
